Data collection for Medicare Beneficiaries Receiving FDG Positron Emission Tomography (PET) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and All Other Cancers
ICR 200811-0938-006 · OMB 0938-0968 · Historical Active
⚠️ Notice: This information collection may be outdated. More recent filings for OMB 0938-0968 can be found here:
Data collection for Medicare Beneficiaries Receiving FDG Positron Emission Tomography (PET) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and All Other Cancers
Extension without change of a currently approved collection
To qualify for payment, providers must prescribe FDG PETs for beneficiaries with a set of clinical criteria specific to each cancer type and stage. CMS is requiring stakeholders including specialty societies, industry, health plans and hospital associations to create systematic clinical data bases or registries to be reimbursed for FDG PETs for beneficiaries. Data elements collected electronically on the associated instrument will be transmitted to CMS for evaluation of the short and long term benefits of FDG PETs to beneficiaries and for use in future clinical decision making.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.